Q-omics provides the consensus-scored MTND2P24 profile across patient tissues and cancer cell-line models. MTND2P24 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MTND2P24 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MTND2P24 RNA expression shows 7,362 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SKCM, KIRC, and ACC as cancer lineages where MTND2P24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND2P24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND2P24 survival associations across molecular data types. MTND2P24 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND2P24 RNA expression–survival associations across cancer types. High MTND2P24 expression shows unfavorable associations in SKCM, THYM and UCEC, but favorable associations in ACC, PAAD and LUSC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for MTND2P24 RNA expression.
This table summarizes MTND2P24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MTND2P24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND2P24 shows lower tumor expression in KIRC and THCA and higher tumor expression in KICH. The KIRC box plot shows higher MTND2P24 RNA expression in normal versus tumor tissue (log2 FC = −0.040, t-test p = .027).
This table shows molecular features associated with MTND2P24 in patient tissues and cancer cell lines. In patient samples, MTND2P24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
